Sugi Predict

Sugi Predict / Compounds / SCHEMBL979911

SCHEMBL979911

SCHEMBL979911

CCCCCC(C)CC[O]

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE2 Q9BYF1 1/20 0.54
▸ OPRM1 P35372 1/20 0.46
▸ LMNA P02545 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ TP53 P04637 1/20 0.41
▸ ADH1B P00325 1/20 0.40
▸ ADH1C P00326 1/20 0.40
▸ ADH1A P07327 1/20 0.40
▸ ADH4 P08319 1/20 0.40
▸ ADH7 P40394 1/20 0.40
▸ FDPS P14324 4/20 0.39
▸ GPR84 Q9NQS5 3/20 0.38
▸ SPHK1 Q9NYA1 1/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ PRKCG P05129 1/20 0.38
▸ PRKCB P05771 1/20 0.38
▸ PRKCA P17252 1/20 0.38
▸ PRKCH P24723 1/20 0.38
▸ PRKCI P41743 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5684482 0.97 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL5687304 0.97 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL976210 0.97 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL1556083 0.97 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL236011 0.97 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL393691 0.92 — —
SCHEMBL980761 0.90 ACE2 (0.54) ACE2OPRM1LMNACA1TP53
SCHEMBL28896926 0.87 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL22749072 0.87 ACE2 (0.57) ACE2OPRM1LMNACA1TP53
SCHEMBL28025558 0.87 ACE2 (0.57) ACE2OPRM1LMNACA1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510500-A Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug 中国海洋大学 2024-02-06 — — CN disclosed
WO-2023223888-A1 METHOD FOR PRODUCING POLYCARBONATE RESIN, AND ALICYCLIC POLYCARBONATE RESIN 旭化成株式会社 2023-11-23 — — WO disclosed
CN-117050043-A 3-phenyl dibenzofuran compound and preparation method and application thereof 中国海洋大学 2023-11-14 — — CN disclosed
CN-116726010-A Application of macrolide derivative in preparation of medicines for inhibiting pro-inflammatory cytokine acting agents 中国海洋大学 2023-09-12 — — CN disclosed
EP-4224243-A1 SPECTACLE LENS Hoya Lens Thailand Ltd. (TH) 2023-08-09 — — EP disclosed
US-20230159727-A1 STERICALLY HINDERED AMINE STABILIZER MIXTURES BASF SE (DE) 2023-05-25 — — US disclosed
US-20230116314-A1 SPECTACLE LENS HOYA LENS THAILAND LTD. (TH) 2023-04-13 — — US disclosed
CN-112851622-B Macrolide brefeldin A ester derivative and application thereof 中国海洋大学 2023-01-10 — — CN disclosed
CN-110651011-B Electronic and optoelectronic component with anisotropy and method for the production thereof 创新实验室有限公司 2022-09-13 — — CN disclosed
WO-2022071482-A1 SPECTACLE LENS ホヤ レンズ タイランド リミテッド 2022-04-07 — — WO disclosed
EP-0763524-B1 Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use SANKYO CO (JP) 2000-08-23 — — EP disclosed
US-6040339-A TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL SANKYO COMPANY, LIMITED (JP) 2000-03-21 — — US disclosed
US-5880147-A Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use SANKYO COMPANY, LIMITED (JP) 1999-03-09 — — US disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 — — US disclosed
US-5614550-A ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS SANKYO COMPANY, LIMITED (JP) 1997-03-25 — — US disclosed
EP-0763524-A1 Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use SANKYO COMPANY LIMITED (JP) 1997-03-19 — — EP disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 — — EP disclosed
US-5534529-A Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 1996-07-09 — — US disclosed
EP-0632036-A2 Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1995-01-04 — — EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159727-A1 STERICALLY HINDERED AMINE STABILIZER MIXTURES PYM1, H1-4, C5 ACE2 2494/4885OPRM1 102/4885LMNA 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.